Lifecore Biomedical vs Maravai LifeSciences
LFCR and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFCR and MRVI compare
Maravai LifeSciences is the larger company, worth 7.8 times as much as Lifecore Biomedical ($1.9B against $242M).
Lifecore Biomedical grew revenue faster over the last twelve months (0.47% versus −5.0% for Maravai LifeSciences).
Lifecore Biomedical keeps more of each dollar of sales as profit, with a net margin of −30.0% compared with −37.1% at Maravai LifeSciences.
Maravai LifeSciences scores higher on the StockData Score (7 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFCR | MRVI |
|---|---|---|
| Size and price | ||
| Market cap | $242M | $1.9B |
| Share price | $6.39 | $7.28 |
| Change, 1 year | −19.7% | 100% |
| Change, 5 years | −26.3% | −82.5% |
| Beta (5Y) | 2.00 | 0.31 |
| Employees | 382 | 435 |
| StockData Score | ||
| Total score | 4 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 | 2 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.9× (better) | 9.1× |
| P/B | – | 9.2× |
| FCF yield | −5.6% | −1.9% (better) |
| Fair value | – | $2.69 |
| Margin of safety | – | −170% |
| Growth | ||
| Revenue growth (TTM) | 0.47% (better) | −5.0% |
| Revenue growth, 5Y average | −4.2% (better) | −8.1% |
| Net income growth (TTM) | −422% | – |
| EPS growth (TTM) | −485% | – |
| Profitability | ||
| Gross margin | 31.3% | 34.9% (better) |
| Operating margin | −13.4% (better) | −56.1% |
| Net margin | −30.0% (better) | −37.1% |
| FCF margin | −10.6% (better) | −17.2% |
| Return on equity | – | −32.9% |
| Return on invested capital | – | −32.4% |
| Financial health | ||
| Debt / equity | – | 0.72 |
| Interest coverage | −0.8× (better) | −4.9× |
| Current ratio | 3.87 | 4.05 (better) |
| Altman Z-score | −0.17 | 4.50 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −9.9% | – |
| Shareholder yield | −9.9% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 67.1% | 55.5% |
| Held by insiders | 46.1% | 3.6% |
| Insider net buying, 12 months | – | $115K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.4% | 5.6% |
Go deeper
- LFCR stock overview
- LFCR income statement
- LFCR valuation and score
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.